Reply: Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size
Brain
.
2024 Oct 3;147(10):e66-e67.
doi: 10.1093/brain/awae246.
Authors
Bruce V Taylor
1
,
Anne-Louise Ponsonby
2
,
Mark Stein
3
,
Robyn Lucas
4
,
Julia Morahan
5
,
Keith Dear
6
,
Helmut Butzkueven
7
Affiliations
1
MS Research FlagshipMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia.
2
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC 3010, Australia.
3
Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Parkville, VIC 3010, Australia.
4
National Centre for Epidemiology and Public Health, Australian National University, Canberra, ACT 0200, Australia.
5
Multiple Sclerosis Australia, North Sydney, NSW 2059, Australia.
6
Department of Statistics, School of Public Health, University of Adelaide, Adelaide, SA 5005, Australia.
7
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.
PMID:
39028680
DOI:
10.1093/brain/awae246
No abstract available
Publication types
Letter
Comment
MeSH terms
Dietary Supplements*
Humans
Multiple Sclerosis* / drug therapy
Sample Size
Vitamin D* / therapeutic use
Substances
Vitamin D
Grants and funding
MS Research Australia